Laquinimod clinical trials
Also written TV-5600.
How each study uses laquinimod is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
15 studies that test it; most in 2010 (4)
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 4 |
| 2013 | 1 |
| 2014 | 3 |
| 2015 | 1 |
| 2021 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 14 · Other 1
Teva Branded Pharmaceutical Products R&D, Inc. (12) · Quan Dong Nguyen (1) · Active Biotech AB (1) · Teva Pharmaceutical Industries, Ltd. (1)
Studies
Open first, then newest update. How each study uses laquinimod is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 15
- Safety, Tolerability, and Distribution of Laquinimod Eye Drops : The LION StudyCompletedPhase 1Quan Dong NguyenNCT06161415Written as Laquinimod eye dropsHow we know
- A Study of Laquinimod Eye-drops in Healthy ParticipantsCompletedPhase 1Active Biotech ABNCT05187403Written as LaquinimodHow we know
- A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) Active Lupus ArthritisCompletedPhase 2Teva Branded Pharmaceutical Products R&D, Inc.NCT01085084Written as LaquinimodHow we know
- BRAVO Study: Laquinimod Double-blind Placebo-controlled Study in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®)CompletedPhase 3Teva Branded Pharmaceutical Products R&D, Inc.NCT00605215Written as LaquinimodHow we know
- A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to PlaceboCompletedPhase 2Teva Branded Pharmaceutical Products R&D, Inc.NCT02284568Written as LaquinimodHow we know
- A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) Active Lupus NephritisCompletedPhase 2Teva Branded Pharmaceutical Products R&D, Inc.NCT01085097Written as LaquinimodHow we know
- A Study to Evaluate the Long-term Safety, Tolerability and Effect of Daily Oral Laquinimod 0.6 mg on Disease Course in Subjects With Relapsing Multiple SclerosisTerminatedPhase 3Teva Branded Pharmaceutical Products R&D, Inc.NCT01047319Written as LaquinimodHow we know
- A Study To Evaluate the Long-Term Safety, Tolerability and Effect on Disease CourseTerminatedPhase 3Teva Branded Pharmaceutical Products R&D, Inc.NCT00988052Written as LaquinimodHow we know
- The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)CompletedPhase 3Teva Branded Pharmaceutical Products R&D, Inc.NCT01707992Written as LaquinimodHow we know
- A Phase I Study in Young Healthy Women to Investigate the Effects of Laquinimod on Standard Oral Contraceptive When Both Treatments Are Given TogetherCompletedPhase 1Teva Branded Pharmaceutical Products R&D, Inc.NCT02085863Written as laquinimodHow we know
- A Study to Evaluate 2 Doses Of Oral Administration Of Laquinimod Compared to Interferon ß-1a Administered by Injection in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)WithdrawnPhase 3Teva Branded Pharmaceutical Products R&D, Inc.NCT01975298Written as LaquinimodHow we know
- Safety and Efficacy of Orally Administered Laquinimod Versus Placebo for Treatment of Relapsing Remitting Multiple Sclerosis (RRMS)CompletedPhase 3Teva Branded Pharmaceutical Products R&D, Inc.NCT00509145Written as LaquinimodHow we know
- A Clinical Study in Participants With Huntington's Disease (HD) to Assess Efficacy and Safety of Three Oral Doses of LaquinimodCompletedPhase 2Teva Branded Pharmaceutical Products R&D, Inc.NCT02215616Written as LaquinimodHow we know
- An Extension Study of LAQ/5062 Exploring the Long Term Safety, Tolerability and Clinical Effect Parameters During the DiseaseTerminatedPhase 2Teva Pharmaceutical Industries, Ltd.NCT00745615Written as LaquinimodHow we know
- Laquinimod Phase IIa Study in Active Crohn's DiseaseCompletedPhase 2Teva Branded Pharmaceutical Products R&D, Inc.NCT00737932Written as LaquinimodHow we know
Codes
What other systems call laquinimod · ClinicalTrials.gg INT004551
- MeSH (NLM) C476223laquinimodOne source NLM
- UNII (FDA) 908SY76S4GLAQUINIMODConfirmed FDA, NLM, Wikidata
- Wikidata Q3487584laquinimodConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C76569LaquinimodOne source FDA
- DrugBank DB06685One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C476223 | laquinimod | One source NLM |
| UNII (FDA) | 908SY76S4G | LAQUINIMOD | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q3487584 | laquinimod | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C76569 | Laquinimod | One source FDA |
| DrugBank | DB06685 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.